key: cord-0295647-8eug1a6s authors: Bojkova, Denisa; Rothenburger, Tamara; Ciesek, Sandra; Wass, Mark N.; Michaelis, Martin; Cinatl, Jindrich title: SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment date: 2022-01-24 journal: bioRxiv DOI: 10.1101/2022.01.20.477067 sha: c5ed752520beb77ce8b45c8d00b640a214a1a167 doc_id: 295647 cord_uid: 8eug1a6s Recently, we have shown that SARS-CoV-2 Omicron virus isolates are less effective at inhibiting the host cell interferon response than Delta viruses. Here, we present further evidence that reduced interferon-antagonising activity explains at least in part why Omicron variant infections are inherently less severe than infections with other SARS-CoV-2 variants. Most importantly, we here also show that Omicron variant viruses display enhanced sensitivity to interferon treatment, which makes interferons promising therapy candidates for Omicron patients, in particular in combination with other antiviral agents. The SARS-CoV-2 Omicron variant (B.1.1.529) causes less severe disease than previous SARS-CoV-2 variants, although immune protection provided by vaccinations and previous infections is reduced against Omicron compared to previous variants [1] [2] [3] [4] . In agreement, evidence is emerging that Omicron is inherently less pathogenic than previous SARS-CoV-2 variants. Omicron variant viruses cause less severe disease in animal studies [5] [6] [7] and Omicron viruses appear to display a lower capacity than other variants to replicate in the lower respiratory tract [7, 8] . Additionally, initial clinical data indicated that the Omicron variant causes less severe disease than previous SARS-CoV-2 variants in unvaccinated individuals [3] . We have most recently shown that Omicron variant viruses are less effective at antagonising the host cell interferon response than Delta variant viruses [9] , which provides a mechanistic explanation for the reduced clinical severity of Omicron disease in individuals without pre-existing adaptive immunity [3] . Omicron virus replication was attenuated relative to Delta virus replication in interferon-competent Caco-2 and Calu-3 cells, but not in interferon-deficient Vero cells, and Omicron viruses caused enhanced interferon promotor activity compared to Delta viruses [9] . Additionally, depletion of the pattern recognition receptor MDA5, which plays a critical role in SARS-CoV-2 detection and interferon response initiation [10] , resulted in increased Omicron virus replication in interferon-competent cells [9] . The exact molecular reasons for the alleviated interferon response antagonism by Omicron viruses remain to be elucidated. Notably, the Omicron and Delta virus isolates that we investigated (see Suppl. Methods) display sequence variants in the viral interferon antagonists nsp3, nsp12, nsp13, nsp14, the membrane (M) protein, the nucleocapsid protein, and ORF3a [11] (Suppl. Table 1 ), which may be of relevance. Here, we show in addition that two SARS-CoV-2 Omicron isolates (Omicron 1, Omicron 2) replicate to lower titres ( Figure 1A ) and induce elevated STAT1 phosphorylation ( Figure 1B) , a key event during interferon signalling, compared to a Delta isolate (B.1.167.2) in Caco-2 and Calu-3 cells [9, 12] (see Suppl. Methods for further information). In A549 cells transduced with ACE2 (SARS-CoV-2 receptor) and TMPRSS2 (mediates SARS-CoV-2 cell entry by cleaving and activating the viral S protein), the Omicron viruses also displayed alleviated infection capacity compared to the Delta virus ( Figure 1C ). This difference largely disappeared upon depletion of both of the pattern recognition receptors MDA5 and RIG-I that mediate the host cell interferon response in virus-infected cells [13] . However, when we compared interferon activity in the supernatants of SARS-CoV-2-infected cells in a HEK-Blue IFNα/β reporter cell assay, the supernatants of Omicron virus-infected RIG-I-knock out cells induced higher interferon promoter activation than the supernatants of Omicron virus-infected MDA5-knock out cells ( Figure 1D ). This is in agreement with data showing that MDA5 is primarily responsible for virus recognition and the induction of an interferon response in SARS-CoV-2-infected cells [10, 13, 14] . Taken together, these findings further confirm that Omicron viruses are less effective than Delta viruses in antagonising the host cell interferon response [9] and that MDA5 is a major player in SARS-CoV-2 recognition [10, 13] . Accordingly, elevated MDA5 levels were detected in the upper airways of SARS-CoV-2-infected individuals with mild or asymptomatic disease [15] . Since Delta has been found to display a similar level of interferon antagonism and sensitivity as previous SARS-CoV-2 variants [16, 17] , the reduced interferon antagonism appears to be unique to Omicron. Most notably, treatment with interferon-a, interferon-b, and interferon-g revealed that the weaker interferon antagonism by Omicron virus isolates translates into a profoundly increased Omicron sensitivity to interferon treatment ( Figure 1E ). Further experiments showed that antiviral interferon-b effects were further increased in combination with nirmatrelvir (the antivirally active agent in paxlovid) and remdesivir ( Figure 1F ). So far, clinical studies reported mixed outcomes in COVID-19 patients treated with different interferons [18] [19] [20] [21] . Given the newly discovered substantially increased interferon sensitivity of Omicron viruses, interferons represent a promising option for the treatment of Omicron patients. In conclusion, we present further evidence that reduced interferon-antagonising activity explains at least in part why Omicron variant infections are inherently less severe than infections with other SARS-CoV-2 variants. Most importantly, we here also show that Omicron variant viruses display enhanced sensitivity to interferon treatment, which makes interferons promising therapy candidates for Omicron patients, in particular in combination with other antiviral agents. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. medRxiv Omicron, the great escape artist SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe Omicron virus causes attenuated infection and disease in mice and hamsters rs.3.rs-1211792 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv Omicron's feeble attack on the lungs could make it less dangerous Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses -are we our own worst enemy? Omicron Variant by Vaccine Sera and Monoclonal Antibodies. medRxiv Differential roles of RIG-I like receptors in SARS-CoV-2 infection SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: A preliminary study The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells Interferon Resistance of Emerging SARS-CoV-2 Variants. bioRxiv Efficacy and safety of pegylated interferon-alpha2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study Effect of a genetically engineered interferonalpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results The authors thank Lena Stegmann, Kerstin Euler and Sebastian Grothe for their technical assistance. This work was supported by the Frankfurter Stiftung für krebskranke Kinder. The authors declare no competing interests.